Controlled Human Exposure to Indoor Air, Dust and Ozone
NCT ID: NCT02017782
Last Updated: 2013-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2013-04-30
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The experiment will document if dust and ozone contribute to deterioration of indoor air quality and to the occurrence of symptoms and health effects.
The study is aimed at testing the hypothesis that the presence of ozone potentiate the health and comfort effects of dust exposure in the indoor environment.
Testing this hypothesis will be based on the following questions:
Does house dust and ozone in concentrations frequently encountered in Danish dwellings cause unwanted health effects either by themselves or by interaction?
If so, does the presence of ozone potentiate the expected irritative effects of dust?
The challenge of these hypotheses will be made as a controlled experiment on humans in a climate chamber under controlled exposure conditions.
This controlled human experiment should be able to substantiate the findings from the intervention studies.
Furthermore, they ideally reflect something relevant to the general public and therefore should have maximum public appeal and application possibilities.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study Group consitss of 24 non-smoking persons(aged 60-70). A controlled, randomized and balanced Latin square cross-over design using the participants as their own controls. The exposures are arranged in a full-scale climate chamber where the participants will be exposed for 5½ hour under controlled environmental conditions.
The exposure facility (Climate chamber):
The exposures are arranged at the controlled experimental facilities at our department which include climate chambers and exposure generators for dust and ozone. The exposure sessions will take place under controlled conditions in a 79 m3 climate chamber made of welded stainless steel optimized for experiments with gasses and particulate air pollutants. The chamber facility allows exposures with controlled ventilation, temperature and air humidity and has an efficient mixing of ventilation air with the chamber air.
All participants will attend all four diff. exposure sessions:
Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (\<20µg/m3). with at least 2 weeks between each exposure session to eliminate hang-over effects. The filtered air and dust and ozone contaminated sessions will be identical except for the air quality. The exposures are unknown to the participants and staff to keep the study double blinded. The blinding will be continued until the basic statistical analyses have been conducted.
Selected subjective and objective health outcomes are measured at baseline and at follow-up at predefined time points.
Health assessment and Measurements includes:
Subjective symptoms, Respiratory outcomes (lung function, FENO, exhaled breath condensate, nasal lavages, Acoustic Rhinometri) Blood samples (inflammation biomarkers)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dust, Ozone, Interaction Dust & Ozone
Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (\<20µg/m3). with at least 2 weeks between each exposure session
Dust
Dust (250-300µg/m3),
Ozone
(0,1ppm ozone),
Interaction Dust & Ozone and placebo Filtered air
Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (\<20µg/m3) with at least 2 weeks between each exposure session.
Dust
Dust (250-300µg/m3),
Ozone
(0,1ppm ozone),
Dust and Ozone
Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
Placebo (Filtered air)
Placebo treatment (Filtered air \<20 ug/m3)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dust
Dust (250-300µg/m3),
Ozone
(0,1ppm ozone),
Dust and Ozone
Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
Placebo (Filtered air)
Placebo treatment (Filtered air \<20 ug/m3)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal lung function
* No active allergic rhinitis
* Be free from clinically significant cardiac, pulmonary, neurological and psychiatric disease as determined by medical history, physical examination and screening investigations.
* With no clinically-significant deviation outside the normal ranges for blood presure and pulse Measurements.
* Capable of giving informed consent
* Be avaible to complete the study
* Provide oral and written informed consent to participate in the study
Exclusion Criteria
* Upper respiratory tract infection within 2 weeks
* Medical conditions likely to affect the outcome of the study in the opion of the investigator.
* Presence of any respiratory disease
* Infection of the upper Airways/lower Airways includingviral infections in the 14 days prior to screening and at the start of/or during the study.
60 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Torben Sigsgaard, Professor
Role: PRINCIPAL_INVESTIGATOR
University of Aarhus, School of Public Health, Dept. of Environment and Occupational Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University, Scholle of Public Health, Dept. of Environmental & Occupational Medicine
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1201
Identifier Type: OTHER
Identifier Source: secondary_id
XDOZ-1201
Identifier Type: -
Identifier Source: org_study_id